Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

OncoPanel™ Assay

Laboratory Developed Test
CGL’s Oncopanel is a next-generation sequencing assay that is offered to provide predictive, prognostic, and diagnostic information for patients with a variety of solid tumours. All the genes targeted by this assay are screened for DNA changes (variants). The clinical significance of variants or variant combinations is then interpreted in the context of therapy-response, prognosis, or diagnostic criteria.
Colorectal Cancer, Gastrointestinal Stromal Tumor, Glioma, Lung Cancer, Melanoma, Ovarian Cancer, Peritoneal Cancer
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset)
See More ...
Next-Generation Sequencing (NGS)